Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 1/20 | 0.74 |
| ▸ | MGLL | Q99685 | 6/20 | 0.72 |
| ▸ | MEN1 | O00255 | 4/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.72 |
| ▸ | MAPT | P10636 | 4/20 | 0.72 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12418181 | 0.88 | PTGS2 (0.65) | SMPD1MGLLMEN1KMT2AMAPT | |
| SCHEMBL2192750 | 0.87 | PTGS2 (0.64) | SMPD1MGLLMEN1KMT2AMAPT | |
| SCHEMBL12418193 | 0.86 | PTGS2 (0.66) | SMPD1MGLLMEN1KMT2AMAPT | |
| SCHEMBL12418189 | 0.85 | MEN1 (0.63) | SMPD1MGLLMEN1KMT2AMAPT | |
| SCHEMBL12418133 | 0.84 | PTGS2 (0.61) | SMPD1MGLLMEN1KMT2AMAPT | |
| SCHEMBL12418134 | 0.84 | PTGS2 (0.61) | SMPD1MGLLMEN1KMT2AMAPT | |
| SCHEMBL12418187 | 0.84 | MAPT (0.62) | SMPD1MGLLMEN1KMT2AMAPT | |
| SCHEMBL12418185 | 0.83 | PTGS2 (0.61) | SMPD1MGLLMEN1KMT2AMAPT | |
| SCHEMBL28294494 | 0.82 | PTGS2 (1.00) | MEN1KMT2AMAPTPTGS2 | |
| SCHEMBL12418135 | 0.81 | PTGS2 (0.58) | SMPD1MGLLMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172207-A1 | SUBSTITUTED PYRAZOLAMIDES AND THEIR USE | AICURIS GMBH & CO. KG (DE) | 2011-07-14 | — | — | US | disclosed |
| US-20110172207-A1 | SUBSTITUTED PYRAZOLAMIDES AND THEIR USE | AICURIS GMBH & CO. KG (DE) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172207-A1 | SUBSTITUTED PYRAZOLAMIDES AND THEIR USE | CACNA1A, P2RX4, KCNH1 | SMPD1 2104/4885MGLL 4690/4885MEN1 2527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.